Why the study?
Does gene expression profiling (GEP) prevent adverse outcomes compared to endomyocardial biopsy in heart transplant patients?
Population
60 heart transplant patients meeting inclusion criteria, starting at 55 days post transplant
Comparison
Gene expression profiling blood test for… vs Endomyocardial biopsy for rejection surveillance…
Design
RCT, randomized
Follow-up
18 months
Authors
Loading...
GEP yields similar outcomes to EMB for rejection surveillance; extends support for noninvasive monitoring in heart transplant care and trials.
Does gene expression profiling (GEP) prevent adverse outcomes compared to endomyocardial biopsy in heart transplant patients?
Gene expression profiling starting at 55 days post-heart transplant appears comparable to endomyocardial biopsy for rejection surveillance without increasing adverse outcomes.
Kobashigawa et al. (2015) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: